Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration.

Antimicrobial Agents and Chemotherapy
Peter HnikKishor M Wasan

Abstract

This study evaluated the safety, tolerability, and pharmacokinetics of a novel oral amphotericin B (AmB) formulation (iCo-019) following single doses to healthy humans. The data from this study suggest that iCo-019 has a long circulation time and systemic exposure without the associated gastrointestinal, liver, and kidney toxicity associated with AmB. This novel oral AmB formulation can serve as a new treatment strategy to overcome the limitations of the use of parenterally administered AmB products.

References

Nov 22, 1993·Drug and Therapeutics Bulletin
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·G DelmasD S Perlin
May 19, 2006·International Journal of Antimicrobial Agents·Michael Kleinberg
Jul 5, 2008·International Journal of Pharmaceutics·Raquel EspadaJuan J Torrado
Apr 29, 2009·The Journal of Antimicrobial Chemotherapy·Pavel GershkovichKishor M Wasan
Jun 24, 2009·The Journal of Infectious Diseases·Kishor M WasanSheila J Thornton
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Vijay Kumar PrajapatiShyam Sundar
Mar 1, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Fady IbrahimKishor M Wasan
Apr 30, 2013·International Journal of Biological Macromolecules·Kuldeep SinghVikas Rana
Jun 4, 2013·International Journal of Pharmaceutics·Acarília Eduardo SilvaE Sócrates T Egito
Dec 6, 2014·TheScientificWorldJournal·Saurabh BhatiaTanmoy Bera
Jan 7, 2015·Molecular Pharmaceutics·Dolores R SerranoIjeoma F Uchegbu
Dec 30, 2015·Drug Delivery and Translational Research·Manisha B ChaudhariVandana B Patravale
Aug 23, 2018·Pharmaceutical Development and Technology·Janet Sui Ling TanNashiru Billa

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.